Capricor Therapeutics, Inc.

Shares of biotech Capricor Therapeutics have <a href="https://www.marketwatch.com/investing/stock/capr?mod=search_symbol">surged</a> 530% over the past month, following the publication of successful results from a <a href="https://www.capricor.com/investors/news-events/press-releases/detail/331/capricor-therapeutics-announces-positive-topline-results">Phase 3 trial of</a> the drug deramyocel against the rare disease Duchenne myodystrophy. If the company receives regulatory approval for the drug, Capricor's shares could rise another 75%, according to Wall Street.

Lyudmila Milevskaya

Writes about:

Articles: 1

Shares of biotech Capricor rose by 530%. Should investors bet on further growth?